These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 11719457

  • 1. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
    Wu R, Zhai Y, Fearon ER, Cho KR.
    Cancer Res; 2001 Nov 15; 61(22):8247-55. PubMed ID: 11719457
    [Abstract] [Full Text] [Related]

  • 2. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas.
    Schwartz DR, Wu R, Kardia SL, Levin AM, Huang CC, Shedden KA, Kuick R, Misek DE, Hanash SM, Taylor JM, Reed H, Hendrix N, Zhai Y, Fearon ER, Cho KR.
    Cancer Res; 2003 Jun 01; 63(11):2913-22. PubMed ID: 12782598
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas.
    Sarrió D, Moreno-Bueno G, Sánchez-Estévez C, Bañón-Rodríguez I, Hernández-Cortés G, Hardisson D, Palacios J.
    Hum Pathol; 2006 Aug 01; 37(8):1042-9. PubMed ID: 16867867
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer.
    Caca K, Kolligs FT, Ji X, Hayes M, Qian J, Yahanda A, Rimm DL, Costa J, Fearon ER.
    Cell Growth Differ; 1999 Jun 01; 10(6):369-76. PubMed ID: 10392898
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rare activation of the TCF/beta-catenin pathway in ovarian cancer.
    Furlong MT, Morin PJ.
    Gynecol Oncol; 2000 Apr 01; 77(1):97-104. PubMed ID: 10739697
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis.
    Irving JA, Catasús L, Gallardo A, Bussaglia E, Romero M, Matias-Guiu X, Prat J.
    Hum Pathol; 2005 Jun 01; 36(6):605-19. PubMed ID: 16021566
    [Abstract] [Full Text] [Related]

  • 14. Abnormalities of the APC/beta-catenin pathway in endometrial cancer.
    Moreno-Bueno G, Hardisson D, Sánchez C, Sarrió D, Cassia R, García-Rostán G, Prat J, Guo M, Herman JG, Matías-Guiu X, Esteller M, Palacios J.
    Oncogene; 2002 Nov 14; 21(52):7981-90. PubMed ID: 12439748
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
    Demunter A, Libbrecht L, Degreef H, De Wolf-Peeters C, van den Oord JJ.
    Mod Pathol; 2002 Apr 14; 15(4):454-61. PubMed ID: 11950921
    [Abstract] [Full Text] [Related]

  • 19. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas.
    Ishizaki Y, Ikeda S, Fujimori M, Shimizu Y, Kurihara T, Itamoto T, Kikuchi A, Okajima M, Asahara T.
    Int J Oncol; 2004 May 14; 24(5):1077-83. PubMed ID: 15067328
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.